2026 Surviving Sepsis Campaign: Key Updates for Adult Sepsis Care

Select Content Type
Briefs
Authored By
Shalina MedSpace
Authored On
Interests
Cardiology
Dermatology
Emergency Medicine
Endocrinology
ENT
Gastroenterology
Hematology
Immunology Allergy & Inflammation
Infectious Disease & Vaccines
Internal/Family Medicine
Neurology
Obstetrics & Gynecology
Oncology
Ophthalmology
Orthopedic
Pain & Anesthesiology
Pediatric Medicine
Psychiatry
Pulmonology
Radiology
Rheumatology
Surgery
Urology & Nephrology
Speciality
Cardiology
Dentistry
Dermatology
Emergency Medicine
Endocrinology
ENT
Gastroenterology
Geriatrics
Hematology
Immunology Allergy & Inflammation
Infectious Disease & Vaccines
Internal/Family Medicine
Medical Genetics
Neurology
Obstetrics & Gynecology
Oncology
Ophthalmology
Orthopedic
Pain & Anesthesiology
Pathology
Pediatric Medicine
Pharmacology
Psychiatry
Public Health
Pulmonology
Radiology
Rheumatology
Surgery
Urology & Nephrology
Thumbnail Image
Sepsis_Thmbnl
Detail Image
Sepsis_Mob det
Book Detail
Actions
Download in App
Countries of release
Ghana
India
Kenya
Nigeria
UAE
Zambia
IS_Ebsco
false
Description

The 2026 Surviving Sepsis Campaign guidelines emphasize early antimicrobial therapy, individualized fluid resuscitation, antimicrobial de-escalation, and avoidance of unproven interventions in adults with sepsis and septic shock. The guidelines recommend prompt antibiotics—ideally within one hour for probable or definite sepsis—along with at least 30 mL/kg of IV crystalloids within three hours for sepsis-induced hypoperfusion or septic shock, with ongoing reassessment to avoid fluid overload. 

Routine empirical antifungal and anaerobic coverage is discouraged without specific risk factors, while several unsupported therapies, including IV vitamin C, probiotics, β-blockers and unnecessary kidney replacement therapy, are not recommended. Overall, the update prioritizes rapid treatment, targeted resuscitation, antimicrobial stewardship and evidence-based care.

Published Date